Join BIOCYTOGEN at AACR-NCI-EORTC INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS 2025
We’re thrilled to announce that we’ll be exhibiting at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2025! Join us from April 27th – 30th in Chicago, Illinois, at this prestigious event where biotechnology companies showcase groundbreaking advancements. With unparalleled networking opportunities, this conference unites innovators, investors, and biopharmaceutical leaders to drive collaboration and accelerate progress in the life sciences industry. We look forward to connecting with you there!
What is AACR-NCI-EORTC INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS 2025?
The AACR Annual Meeting is the most important cancer meeting in the world, where members of the global cancer research community gather to interact, collaborate, and share the latest breakthroughs in cancer science and medicine. The AACR Annual Meeting offers an opportunity to increase the visibility of your organization among the world’s most prestigious scientists and other cancer professionals. Annual Meeting attendees are laboratory scientists and clinical investigators specializing in all aspects of cancer research, including experimental therapeutics, molecular targeted therapies, chemistry, molecular biology and genetics, immunology and immunotherapy, tumor biology, virology, toxicology, prevention, and clinical and translational research.
Event Overview
Date: April 27th – 30th
Venue: McCormick Place Convention Center, Chicago, Illinois. 2301 S King Dr, Chicago, IL 60616.
Event Schedule
The AACR-NCI-EORTC INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS 2025 in Chicago, Illinois will showcase a diverse array of speakers and topics. For a comprehensive look at the daily schedule, including session times and detailed information on each presentation, please refer to the AACR-NCI-EORTC INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS 2025 agenda.
About BIOCYTOGEN
Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).
We look forward to seeing you at the AACR-NCI-EORTC INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS 2025 in Chicago, Illinois!
